Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.biomaterials.2013.09.043
Title: Cetuximab conjugated vitamin E TPGS micelles for targeted delivery ofdocetaxel for treatment of triple negative breast cancers
Authors: Kutty, R.V.
Feng, S.-S. 
Keywords: Biodegradable polymers
Cancer nanotechnology
Drug targeting
Molecular biomaterials
Nanomedicine
Pharmaceutical nanotechnology
Issue Date: Dec-2013
Citation: Kutty, R.V., Feng, S.-S. (2013-12). Cetuximab conjugated vitamin E TPGS micelles for targeted delivery ofdocetaxel for treatment of triple negative breast cancers. Biomaterials 34 (38) : 10160-10171. ScholarBank@NUS Repository. https://doi.org/10.1016/j.biomaterials.2013.09.043
Abstract: We developed a system of Cetuximab-conjugated micelles of vitamin E TPGS for targeted delivery of docetaxel as a model anticancer drug for treatment of the triple negative breast cancer (TNBC), which shows no expression of either one of the hormone progesterone receptor (PR), estrogen receptor (ER) and epidermal growth factor receptor 2 (HER2) and is thus more difficult to be treated than the positive breast cancer. Such micelles are of desired particle size, drug loading, drug encapsulation efficiency and drug release profile. Their surface morphology, surface charge and surface chemistry were also characterized. The fibroblast cells (NIH3T3), HER2 overexpressed breast cancer cells (SK-BR-3), ER and PR overexpressed breast cancer cells (MCF7), and TNBC cells of high, moderate and low EGFR expression (MDA MB 468, MDA MB 231 and HCC38) were employed to access invitro cellular uptake of the coumarin 6 loaded TPGS micelles and cytotoxicity of docetaxel formulated in the micelles. The high IC50 value, which is the drug concentration needed to kill 50% of the cells in a designated period such as 24h, obtained from Taxotere® showed that the TNBC cells are indeed more resistant to the free drug than the positive breast cancer cells. However, the therapeutic effects of docetaxel could be greatly enhanced by the formulation of Cetuximab conjugated TPGS micelles, which demonstrated 205.6 and 223.8 fold higher efficiency than Taxotere® for the MDA MB 468 and MDA MB 231 cell lines respectively. © 2013 Elsevier Ltd.
Source Title: Biomaterials
URI: http://scholarbank.nus.edu.sg/handle/10635/88632
ISSN: 01429612
DOI: 10.1016/j.biomaterials.2013.09.043
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

50
checked on Dec 4, 2018

WEB OF SCIENCETM
Citations

48
checked on Dec 4, 2018

Page view(s)

32
checked on Oct 5, 2018

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.